Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
about
Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimeticA novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitroRolling circle amplification: a versatile tool for chemical biology, materials science and medicineA hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibodyModern Technologies for Creating Synthetic Antibodies for Clinical application.Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancerImproving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityMultiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasEvaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell linesMonoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric NanomedicinesCell death signaling and anticancer therapyAnti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosisAssociation of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cellsAnti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.Advances and challenges in developing cytokine fusion proteins as improved therapeutics.Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.Current options to manage Waldenström's macroglobulinemia.Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity.A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines.Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency.DNA-scaffolded multivalent ligands to modulate cell function.
P2860
Q27665886-8155CCD4-E447-4AC2-AEEB-765905EC2147Q28728917-05AAC2AB-9BAC-43C1-91A0-178B755F984AQ29543898-C2BF6314-8EA0-4D90-AF30-B2000FECA393Q30420026-4BF8CDC0-8B5E-4D73-A06E-2770220BC43EQ30467308-6EC84250-45C8-4DBE-AAB6-153234C3D722Q33587482-CCA3FD3F-EE8C-4FB1-BECD-EB729FB6AA1CQ33645793-CA20D9A3-49A9-4309-83FB-AF16009AF882Q33896738-9730FF56-DAA9-4709-A646-D4E8F36B8D08Q34369841-C94C3C77-F2AA-4995-B3CC-48B4803A6A0FQ34406479-CA0D3A3D-99E0-4517-930B-952DC53449EBQ34700655-37586C26-24BA-4875-89B4-34E3C61D4021Q34999743-9A7BDC56-91A9-4CBE-800D-5A0FBCED8DF6Q35172476-DDFBF3C2-6E61-492D-91B2-4EFA5CF9D3FEQ35861726-59EF250B-4162-44CA-97CE-230D45C207A5Q35972102-855B8FE3-9962-4313-B9F3-F83EC119115BQ36611125-4B47E2F3-BE82-4B0F-A20B-0A9DF8294C1CQ37022297-F28F9DF0-5749-4B36-8F26-7F6BF4D9A4C3Q37088489-F3633C0F-2B34-4F65-BFF2-C52143C63652Q37234627-E97B7A0D-396F-4562-8F52-E49CD5E41D96Q37698921-38850DF0-8AE7-41DF-BEC2-1888870E0591Q37720857-1DF1C9EF-EA9B-4FD2-ABB0-B3D74526F751Q38088357-2B2DB3FD-1FE7-4532-9248-9AD3EF8FC5D1Q38790644-4CCB154A-3A88-43B7-8E1C-57BA7098C476Q38807514-7F4ABCCA-C1DB-4C0F-A609-71A8926E1344Q39358109-3FD0683D-794B-49CC-89A5-7F7A85311F40Q39455947-26DBE770-7289-4076-9EC3-F28480705570Q39562454-4987086B-6D46-4E49-BF45-4AB31ECFF8EAQ40976323-8AA70763-43DE-4431-A373-9697B372273AQ41791356-B07FEB5A-98F7-438C-A4CE-0F13720B9E6DQ46196202-A62584FB-D213-42C6-9538-C6A3789F1124
P2860
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Novel designs of multivalent a ...... mproved lymphoma therapeutics.
@en
Novel designs of multivalent a ...... mproved lymphoma therapeutics.
@nl
type
label
Novel designs of multivalent a ...... mproved lymphoma therapeutics.
@en
Novel designs of multivalent a ...... mproved lymphoma therapeutics.
@nl
prefLabel
Novel designs of multivalent a ...... mproved lymphoma therapeutics.
@en
Novel designs of multivalent a ...... mproved lymphoma therapeutics.
@nl
P2093
P1433
P1476
Novel designs of multivalent a ...... mproved lymphoma therapeutics.
@en
P2093
Chien-Hsing Chang
David M Goldenberg
Edmund A Rossi
Rhona Stein
Thomas M Cardillo
P304
P356
10.1158/0008-5472.CAN-08-2033
P407
P577
2008-10-01T00:00:00Z